HIV or HCV detection with CRISPR-CAS13A

US12215377B2 · kind B2 · utility

Assignees

• The J. David Gladstone Institute, a testamentary trust established under the Will of J. David Gladstone · US
• The Regents of the University of California · US

Inventors

• Parinaz Fozouni · San Francisco, US
• Melanie Ott · Mill Valley, US
• Jennifer A. Doudna · Berkeley, US

Key dates

• Filing date: Sep 6, 2019
• Grant date: Feb 4, 2025
• Expiry date: Apr 6, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/158
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The present disclosure relates to methods using CRISPR-Cas13a enzyme, complexed with HIV or HCV crRNAs to specifically and sensitively detect and quantify the presence of HIV or HCV RNA in a sample. These methods can be used to diagnose HIV or HCV infection, quantify the concentration of HIV or HCV RNA present in a sample, identify the presence of different HIV or HCV splice variants, subtypes, or mutations, and to monitor reactivation of HIV or HCV transcription.